Influence ofNAT2Polymorphisms on Sulfamethoxazole Pharmacokinetics in Renal Transplant Recipients
Authors:
- 1 February 2012
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (2) , 825-829
Abstract
The sulfamethoxazole (SMX)-trimethoprim drug combination is routinely used as prophylaxis againstPneumocystispneumonia during the first 3 to 6 months after renal transplantation. The objective of this study was to examine the impact ofN-acetyltransferase 2 (NAT2) andCYP2C9polymorphisms on the pharmacokinetics of SMX in 118 renal transplant recipients. Starting on day 14 after renal transplantation, patients were administered 400 mg/day-80 mg/day of SMX-trimethoprim orally once daily. On day 14 after the beginning of SMX therapy, plasma SMX concentrations were determined by a high-performance liquid chromatography method. The SMX area under the concentration-time curve from 0 to 24 h (AUC0-24) for 15 recipients with theNAT2slow acetylator genotype (NAT2*5/*6, -*6/*6, -*6/*7, and -*7/*7) was significantly greater than that for 56 recipients with theNAT2rapid acetylator genotype (homozygous forNAT2*4) (766.4 ± 432.3 versus 537.2 ± 257.5 μg-h/ml, respectively;P= 0.0430), whereas there were no significant differences in the SMX AUC0-24between theCYP2C9*1/*1and -*1/*3groups. In a multiple regression analysis, the SMX AUC0-24was associated withNAT2slow acetylator polymorphisms (P= 0.0095) and with creatinine clearance (P= 0.0499). Hepatic dysfunction inNAT2slow acetylator recipient patients during the 6-month period after SMX administration was not observed. SMX plasma concentrations were affected byNAT2polymorphisms and renal dysfunction. Although standard SMX administration to patients withNAT2slow acetylator polymorphisms should be accompanied by monitoring for side effects and drug interaction effects from the inhibition of CYP2C9, SMX administration at a low dose (400 mg) as prophylaxis may not provide drug concentrations that reach the level necessary for the expression of side effects. Further studies with a larger sample size should be able to clarify the relationship between SMX plasma concentration and side effects.Keywords
This publication has 22 references indexed in Scilit:
- NAT2*7 Allele Is a Potential Risk Factor for Adult Brain Tumors in Taiwanese PopulationCancer Epidemiology, Biomarkers & Prevention, 2008
- Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse events with co-trimoxazole in Japanese patients with systemic lupus erythematosusArthritis Research & Therapy, 2007
- Genotypes of vitamin K epoxide reductase, γ-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patientsThrombosis Research, 2007
- Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohortClinical Biochemistry, 2006
- Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patientsJournal of Human Genetics, 2006
- Trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipientsBritish Journal of Clinical Pharmacology, 2005
- MOLECULAR MECHANISMS OF GENETIC POLYMORPHISMS OF DRUG METABOLISMAnnual Review of Pharmacology and Toxicology, 1997
- Synthesis and reactions of nitroso sulphamethoxazole with biological nucleophiles: Implications for immune mediated toxicityBioorganic & Medicinal Chemistry Letters, 1996
- Genetic polymorphisms in xenobiotic metabolismEuropean Journal of Cancer, 1994
- In vitrocytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIVClinical and Experimental Immunology, 1993